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Calls for professional accountability have resulted in the development of ethics guidelines by
numerous specialty and subspecialty groups of scientists. Indeed, guidelines among some health
professions now address vulnerable and dependent groups; but these are silent on issues related
to biomarkers. In parallel, attention has been drawn to human rights concerns associated with
attempts to detect hypersusceptible workers, especially in democratic countries. Despite this,
concern for vulnerable populations grows as advances in biomarker technology make the
identification of genetic predisposition and susceptibility markers of both exposure and outcome
more attainable. In this article, the principles derived from the ethical theory of utilitarianism
provide the basis for principle-based ethical analysis. In addition, the four principles of biomedical
ethics-respect for autonomy, beneficence, nonmaleficence, and social justice are considered
for biomarker studies. The need for a context in which ethical analysis is conducted and from
which prevailing social values are shown to drive decisions of an ethical nature is emphasized;
these include statutory regulation and law. Because biomarker studies can result in more harm
than good, special precautions to inform research participants prior to any involvement in the use
of biomarkers are needed. In addition, safeguards to maintain the privacy of data derived from
biomarker studies must be developed and implemented prior to the application of these new
technologies. Guidelines must be expanded to incorporate ethical, social, and legal considerations
surrounding the introduction of new technologies for studying susceptible populations and
individuals who may be vulnerable to environmental exposures. Environ Health Perspect
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Introduction to Professional
Conduct
The need, among others, to be publicly
accountable has led many professions to
develop guidelines, declarations, or codes
of ethics and, in some instances, standards
of practice. These statements on appro-
priate professional conduct document the
normative practices against which the
profession can be held accountable for its
actions, both collectively and by its
individual practitioners (1).
The phenomenon of developing
codes/guidelines is relatively recent, having
become common practice within only the
past decade. Hence, many ofthe codes are
very recent, e.g., those promulgated by the
International Commission on Occupational
Health (ICOH) (2) and the Council for
International Organizations of Medical
Sciences (CIOMS) (3,4). It is therefore
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useful to examine them to see what
guidance has been incorporated on issues
dealing with susceptible groups ofpeople
and/or individuals. Ofparticular note is the
attention given in these recent documents
to vulnerable populations.
Advances in professional (or, applied)
ethics are made by thoughtful and in-
novative thinkers (or, visionaries) in any
activity area within the broad array of
professional endeavor. However, it is only
once the deliberations of these so-called
visionaries are ultimately integrated into
the profession's codes/guidelines, that they
will be deemed "common practice," or
normative. Hence, this article also exam-
ines the more recent published and pre-
sented works by leading contributors to
the philosophy of biomarkers for the
screening ofpopulations (5-66). The lat-
ter exercise is intended to identify future
ethical, social, and legal directions in the
area ofstudies ofsusceptible populations
and individuals. Matters that focus
directly on the science and/or technology
ofbiomarkers do not fall within the scope
ofthis article.
Extant Guidelines
The four principles upon which much
health-related ethical analysis is conducted
are respect for autonomy (respect for per-
sons, embracing the need for prior, volun-
tary, fully informed consent), beneficence
(doing good), nonmaleficence (doing no
harm), and distributive justice (social jus-
tice or equity vis i vis the equal allocation
ofrisks and benefits).
While recent international guidelines
are silent on the issue ofbiomarker studies
per se, the CIOMS (1991) guidelines do
state, consistent with the principle of non-
maleficence, that harm to the individual
should be minimized (3). Specifically (and
of relevance to genetic testing), "Ethical
review must always assess the risk ofsub-
jects or groups suffering stigmatization,
prejudice, loss ofprestige or self-esteem, or
economic loss as a result oftaking part in a
study..." (principle 19). With regard to
groups (principle 21), "Epidemiological
studies may inadvertently expose groups as
well as individuals to harm, such as eco-
nomic loss, stigmatization, blame, or with-
drawal of services. Investigators who find
sensitive information that may put a group
at risk of adverse criticism or treatment
should be discreet in communicating and
explaining their findings...."
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Concerning "vulnerable and dependent
groups," the CIOMS (1991) guidelines
state:
Ethical review committees should be
particularly vigilant in the case ofpro-
posals involving populations primarily of
children, pregnant and nursing women,
persons with mental illness or handicap,
members of communities unfamiliar
with medical concepts, and persons with
restricted freedom to make truly inde-
pendent choices, such as prisoners and
medical students. Similar vigilance is
called for in the case ofproposals for
invasive research with no direct benefit
to its subjects (principle 43) (4).
It is only the latter portion of this
principle that could be seen to be ofpartic-
ular relevance to biomarker research and its
applications. CIOMS (1993) addresses this
issue under its guideline no. 10, "Selection
of research subjects: equitable distribution
of burdens and benefits." It states, " ...
Special justification is required for inviting
vulnerable individuals and, if they are
selected, the means of protecting their
rights and welfare must be particularly
strictly applied."
On the subject of "biological monitor-
ing and investigations," (principle 12) the
most relevant guidelines for professionals
engaged in occupational health and safety
(ICOH, 1996) states:
Biological tests and other investigations
must be chosen from the point ofview of
their validity for protection ofthe health
ofthe worker concerned, with due regard
to their sensitivity, their specificity and
their predictive value. Occupational (and
environmental) health professionals must
not use screening tests or investigations
which are not reliable or which do not
have a sufficient predictive value in rela-
tion to the requirements of the work
assignment. Where a choice is possible
and appropriate, preference must always
be given to noninvasive methods and to
examinations which do not involve any
danger to the health ofthe worker con-
cerned. An invasive investigation or an
examination which involves a risk to the
health ofthe worker concerned may only
be advised after an evaluation of the
benefits and the risks involved and can-
not be justified in relation to insurance
claims. Such an investigation is subject to
the worker's informed consent and must
be performed according to the highest
professional standards.
[Note: Because the ICOH document
confines itself to occupationally exposed
groups, all quoted statements from this
document will be expanded to incorporate
environmental health where appropriate, in
parentheses within anyquotation.]
Guidelines are not an end in themselves;
they are expected to be reviewed and
revised from time to time to reflect chang-
ing values and to rise to the challenge pre-
sented from advances in technology that so
often precipitate the need for concern
about ethical conduct. With biomarker
technology gaining prominence, a lag of
some years can be anticipated before the
ethics guidelines/codes ofconduct are seen
to address related issues.
Social and Legal Perspectives
The context for considering ethical issues is
important for the analysis of an ethical
dilemma. Context can shed light on which
ethical principles ought to take precedence
over others. Hence, the context ofoccupa-
tional and environmental health will be
addressed first.
The aim ofoccupational and environ-
mental health practice is to protect health
and to promote the establishment and
maintenance ofa safe and healthy environ-
ment. In addition, in the occupational
health context in particular, the aim is to
promote the adaptation ofwork to the
capabilities ofworkers, taking into account
their state ofhealth. Attention in guide-
lines thus should be given to vulnerable
groups and to underserved working popu-
lations (43). Occupational health is essen-
tially preventive and should help the
workers, individually and collectively, to
safeguard their health in their employment.
It should thereby help the enterprise to
ensure healthy and safe working conditions
and environment, which are criteria ofeffi-
cient management and are to be found in
well-run enterprises.
The field of occupational health is
comprehensive and covers the prevention
ofall impairments arising out ofemploy-
ment, work injuries, and work-related dis-
eases as well as all aspects relating to the
interactions between work and health.
Occupational health professionals should
be involved, whenever possible, in the
design of health and safety equipment,
methods, and procedures and they should
encourage workers' participation in this
field. Occupational health professionals
have a role to play in the promotion of
workers' health and should assist workers
in obtaining and maintaining employment
notwithstanding their health deficiencies
or their handicap. The word "workers" is
used here in a broad sense and covers all
employees, including management and the
self-employed.
The approach in both occupational and
environmental health is multidisciplinary
and intersectoral. There is a wide range of
obligations and complex relationships
among those concerned (2). It is therefore
important to define the role ofprofession-
als and their relationships with other pro-
fessionals, with other health professionals
and with social partners in the purview of
economic, social, and health policies devel-
opment. This calls for a clear view about
the ethics ofoccupational and/or environ-
mental health professionals and standards
in their professional conduct.
In occupational settings in general,
duties and obligations are defined by statu-
tory regulations. Each employer has the
responsibility for the health and safety of
the workers in his or her employment. In
particular, in the United States it is the
obligation of the employer to provide a
safe and healthful workplace (67). More
recent interpretation of this legislation
points to environmental control as
opposed to worker exclusion for meeting
this obligation.
Each profession has its responsibilities
that are related to the nature of its duties.
When specialists ofseveral professions are
working together within a multidiscipli-
nary approach, it is important that they
base their action on some common princi-
ples ofethics and that they have an under-
standing of each others' obligations,
responsibilities and professional standards.
Special care should be taken with respect to
ethical aspects, in particular when there are
conflicting rights such as the right to the
protection ofemployment and the right to
the protection ofhealth, the right to infor-
mation and the right to confidentiality, as
well as individual rights and collective
rights (2).
Some ofthe conditions ofexecution of
the functions ofoccupational health pro-
fessionals and the conditions ofoperation
of occupational health services are often
defined in statutory regulations. One ofthe
basic requirements for a sound occupational
health practice is full professional indepen-
dence, i.e., that occupational health profes-
sionals must enjoy independence in the
exercise of their functions that should
enable them to make judgments and give
advice for the protection of the workers'
health and for theirsafetywithin the under-
taking in accordance with their knowledge
and conscience (2). The analogous argu-
ments could be made in support of the
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independence ofthe environmental health
practitioner in protecting the interests of
public health.
There are basic requirements for
acceptable occupational health practice.
These conditions of operation are some-
times specified by national regulations and
include, in particular, free access to the
work place, the possibility of taking
samples and assessing the working envi-
ronment, making job analyses and partici-
pating in inquiries after an accident, and
the possibility to consult the competent
authority on the implementation of
occupational safety and health standards in
the undertaking. Occupational health
professionals should be allocated a budget
that will enable them to carry out their
functions according to good practice and to
the highest professional standards. This
should include adequate staffing, training,
and retraining; support, and access to
relevant information and to an appropriate
level of senior management (2). These
arguments can be extended to environmental
health professionals.
Ethical Considerations
Ethical analysis often points to tensions
between two or more principles. For
example, the need for individual privacy
can conflict with the need to protect the
public interest; and, the need to do good
has to be balanced against the potential also
to cause harm. Because ofthis, a review of
the strengths and weaknesses of the
advances that biomarker technology brings
must be considered.
Epidemiology has relied on hard end
points such as death in most cohort
studies. However, workers might prefer to
see something different from body counts
when the potential health effects of occu-
pational exposures are studied (31,57).
Likewise, the public might prefer to see
something different from body counts
when the potential health effects from
environmental exposures are studied.
Therefore, more direct indicators ofboth
exposure and early response (or outcome)
would have some advantages. Biological
markers provide just such a tool.
The use of biological markers, such as
lead levels in blood or liver function tests,
is not new in occupational or environmen-
tal epidemiology. However, the use of
molecular techniques in epidemiological
studies has made possible the use of
biomarkers to assess target organ exposure
for determining susceptibility and for
establishing early disease.
Potential uses of biomarkers in the
context ofoccupational and environmental
epidemiology include the following (31,57):
* exposure assessment in cases in which
traditional epidemiologic tools are
insufficient (particularly for low doses
and low risks)
* multiple exposures or mixtures, in
which the aim is to disentangle the
causative role ofsingle chemical agents
or substances
* estimation ofthe total burden ofexpo-
sure to chemicals that have the same
mechanistic target
* investigation of pathogenetic mecha-
nisms
* study of individual susceptibility (e.g.,
metabolic polymorphisms, DNA
repair)
* an increase in statistical power owing to
more accurate classification ofexposure
and/or disease.
In reference to the latter point,
biomarkers can be highly specific indica-
tors ofa cause ofa disease that otherwise
has multiple causes. For example, determi-
nation of the relationship among specific
patterns of chromosomal abnormalities in
chemical-induced leukemia can improve
the likelihood ofdetermining a cause-and
effect-relationship in a cluster ofleukemias
or, as another example, study ofthe codons
involved in p53 mutations could lead to
distinguishing between those lung cancers
from radon and those from cigarette smok-
ing, a point ofmuch value in determining
radon risk.
Great enthusiasm has arisen in the
scientific community about these uses but,
as noted above, methodological complexity
should serve to caution against excessive
optimism. Biomarkers of chemical expo-
sures (such as DNA adducts) have several
shortcomings (31,35,57).
a) They usually reflect recent exposures
and, therefore, are of limited use in
case-control studies, whereas they require
repeated samplings over prolonged periods
for use in cohort investigations. b) While
they can be highly specific and thus improve
exposure classification, findings often
remain difficult to interpret. c) When com-
plex chemical exposures, e.g., air pollution
or environmental tobacco smoke are investi-
gated, it is possible that the biomarker
would reflect one particular component of
the mixture, whereas the biological effect, in
fact, could have arisen from another compo-
nent ofthe mixture. d) In many situations,
it is not clear whether a biomarker reflects a
relevant exposure, a correlate ofthe relevant
exposure, individual susceptibility, or an
early disease stage, thus limiting causal infer-
ence. e) The determination of most bio-
markers requires an expensive test or an
invasive procedure or both, thus creating
constraints for adequate study size and sta-
tistical power. f) A biomarker ofexposure
is no more than a proxy for the real objec-
tive of an epidemiological investigation
which, as a rule, focuses on an avoidable
environmental exposure (31,56,57).
Even more important than the
methodological shortcomings is the con-
sideration that molecular techniques might
cause us to redirect our focus from identi-
fying risks in the exogenous environment
to identifying high-risk individuals and
then making personalized risk assessments
by measuring phenotype, adduct load, and
acquired mutations. This would direct our
focus to a form of clinical evaluation
rather than one of public health epidemi-
ology. Focusing on individuals could dis-
tract us from the important public health
goal of creating a less hazardous environ-
ment. Clearly, there are both potential
benefits and potential harms from the use
ofbiomarker technology.
At least two early critiques of the view
that supported the advancement of tech-
nologies whose goal it was to detect hyper-
susceptible workers have pointed to the
sociopolitical context ofsuch technologies
(10,16). In fact, Green (16) examined the
earlier concept of the hypersusceptible
worker, arguing that the "concept enabled
industrial toxicologists to organize knowl-
edge about workers' reactions to toxicity so
as to sustain a professional and method-
ological ideology which reflects the rela-
tionship between industrial toxicology and
capitalist industry." Atherley (10) presents
an example (i.e., lead) of the erosion of
human rights by certain legislated activities
in occupational medicine, concluding that
issues relating to medical monitoring com-
prise political and ethical issues, not merely
technical ones, that should be debated
publicly. Both Green and Atherley,
whether invoking examples from audiome-
try and radiographs (X-rays) ofthe back to
glucose 6-phosphate dehydrogenase and
serum-a-1-antitrypsin deficiency, conclude
that none of these markers satisfy even
those criteria specified by the proponents
of such tests (10,16); this view also has
more recent support (56,57).
Ethical Directions
Two further important issues emerge
regarding the use ofbiomarkers (31). First,
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the use ofbiomarkers in both occupational
and environmental epidemiology must be
accompanied by a clear policy as far as
informed consent is concerned. In the
occupational setting, the worker may have
several reasons to refuse cooperation. One
very practical reason is that the identifica-
tion of, say, an alteration in an early
response marker (such as sister chromatid
exchange) is not recognized by insurance
companies as an occupational disease, but
private insurers might shun the worker
because he/she may be more prone to
disease. A second reason concerns genetic
screening: since the distributions ofgeno-
types and phenotypes vary according to
ethnic group, occupational opportunities
for minorities might be hampered by
genetic screening. Third, doubts can be
raised about the predictability of genetic
tests: since the predictive value depends on
the prevalence of the condition that the
test aims to identify, ifthe latter is rare, the
predictive value will be low and the prac-
tical use of the screening test will be
questionable, with a high rate of false
positives (12). To date, none ofthe genetic
screening tests have been judged applicable
in the field (6,10,11,16,35,56).
The second issue that emerges concern-
ing use ofbiomarkers is that ethical princi-
ples must be applied prior to the use of
biomarkers. Recently, these principles were
considered for biomarkers used for identify-
ing individual susceptibility to disease. An
interdisciplinary Working Group of the
Technical Office of the European Trade
Unions with the support of the Com-
mission ofthe European Communities has
reinforced the view that tests can be con-
ducted onlywith the objective ofpreventing
disease in a workforce (68). Among other
considerations, the use oftests must never
a) serve as a means for selection of the
fittest; b) be used to avoid implementing
effective preventive measures, notably the
need to eliminate or reduce hazardous con-
ditions in the workplace or in the environ-
ment; c) create, confirm, or reinforce social
inequality; d) create a gap between the ethi-
cal principles followed in theworkplace or in
the environment and the ethical principles
that must be upheld in a democratic society;
or e) oblige a person seeking employment to
disclose personal details other than those
strictly necessary for obtaining thejob (57).
Finally, evidence is accumulating that
the metabolic activation or inactivation of
hazardous substances (and of carcinogens
in particular) varies considerably in human
populations and is partly genetically deter-
mined. Furthermore, interindividual vari-
ability in susceptibility to carcinogens may
be particularly important at low levels of
occupational and environmental exposure
(59). The implications ofthese findings for
regulatory decisions that focus the risk
assessment process on the most susceptible
are obvious (61).
Where professional groups are slow or
reluctant to exercise due restraint in the
application of new technologies (such as
biomarkers), governments are likely to
intervene with legislation in the public
interest. It therefore behooves thoughtful
professionals to consider the application of
biomarkers in their professional interests
and to develop guidelines for their use.
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